Toripalimab-Tpzi: uses, dosing, side effects & brands
Toripalimab-Tpzi is a medicine sold in the U.S. under one brand, for nasopharyngeal carcinoma. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Nasopharyngeal Carcinoma
- Available as
- Injectable
- Sold as
- Loqtorzi
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
How toripalimab-tpzi is dosed
From the FDA label for Loqtorzi (application BLA761240). Other toripalimab-tpzi products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
In combination with cisplatin and gemcitabine: 240 mg intravenously every three weeks ( 2.1 ) As a single agent: 3 mg/kg intravenously every two weeks ( 2.1 ) First Infusion : Infuse over 60 minutes. Subsequent Infusions : If no infusion-related reactions occurred during the first infusion, subsequent infusions may be administered over 30 minutes. 2.1 Recommended Dosage The recommended dosages of LOQTORZI are provided in Table 1. Administer as recommended [see Dosage and Administration (2.3) ]. Table 1: Recommended Dosage Indication Recommended Dosage of LOQTORZI Duration of Treatment First-line NPC 240 mg every three weeks Until disease progression, unacceptable toxicity, or up to 24 months. Recurrent NPC 3 mg/kg every two weeks Until disease progression or unacceptable toxicity. 2.2 Dosage Modifications No dose reductions of LOQTORZI are recommended. In general, withhold LOQTORZI for severe (Grade 3) immune-mediated adverse reactions. Permanently discontinue LOQTORZI for life-threatening (Grade 4) immune-mediated adverse reactions, recurrent severe (Grade 3) immune-mediated reactions that require systemic immunosuppressive treatment, or an inability to reduce prednisone to 10 mg per day or less (or equivalent) within 12 weeks of initiating steroids. Dosage modifications for LOQTORZI for adverse reactions that require management different from these general guidelines are…
Toripalimab-Tpzi side effects
The following clinically significant adverse reactions are described elsewhere in the labeling: Severe and fatal immune-mediated adverse reactions [see Warnings and Precautions (5.1) ] Infusion-related reactions [see Warnings and Precautions (5.2) ] Complications of Allogeneic HSCT [see Warnings and Precautions (5.3) ] LOQTORZI in Combination with Cisplatin and Gemcitabine The most common adverse reactions (≥ 20%) are nausea, vomiting, decreased appetite, constipation, hypothyroidism, rash, pyrexia, diarrhea, peripheral neuropathy, cough, musculoskeletal pain, upper respiratory infection, insomnia, dizziness, and malaise. ( 6.1 ) LOQTORZI as a Single Agent The most common adverse reactions (≥ 20%) are fatigue, hypothyroidism and musculoskeletal pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Coherus Oncology, Inc. at 1-800-483-3692 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described in the WARNINGS AND PRECAUTIONS section reflect exposure to LOQTORZI at a dose of 240 mg every 3 weeks in combination with up to 6 cycles of cisplatin and gemcitabine, followed…
Who shouldn’t take toripalimab-tpzi
None . None
Every toripalimab-tpzi product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Loqtorzi.
Related calculators
Frequently asked questions
What is toripalimab-tpzi?
Loqtorzi (Toripalimab-Tpzi) is a medication used to treat Nasopharyngeal Carcinoma.
Can you take toripalimab-tpzi with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run toripalimab-tpzi against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does toripalimab-tpzi come in?
Across the brands we track, toripalimab-tpzi is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic toripalimab-tpzi?
We do not currently list a generic-labelled toripalimab-tpzi product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Toripalimab-Tpzi: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/toripalimab-tpzi
- MLA
- “Toripalimab-Tpzi: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/toripalimab-tpzi.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for toripalimab-tpzi on DailyMed (NIH) ↗.